83% of patients (n=43) underwent surgery within 6-weeks of completion of neoadjuvant treatment (median: 30 days; IQR 27-34).Conclusions:The neoadjuvant breast cancer optimal care timeframes were feasible to achieve in a regional and rural setting. However, further targeted research is needed to...
Breast cancer (BC) treatments and related symptoms may affect return to work (RTW). The objective of this study was to investigate the impact of BC care pathways (timing and sequence of treatments) and related symptoms on RTW. The study population includ
2. Current landscape of therapeutic vaccines for breast cancer 3. Vaccines targeting HER2 in breast cancer 4. Vaccines targeting triple-negative breast cancer 5. Vaccines targeting HR-positive breast cancer 6. Vaccines targeting breast cancer irrespective of the biological subtype 7. Other targets for...
From: The patient-breast cancer care pathway: how could it be optimized? Original Submission 22 Mar 2015 Submitted Original manuscript Resubmission - Version 2 Submitted Manuscript version 2 Author responded Author comments Resubmission - Version 3 Submitted Manuscript version 3 Publishing 5 May 2015 Ed...
IGF1R signaling results in activation of downstream effectors of the AKT-pathway and MAPK-pathway that function to control mRNA translation in breast cancer [4], [7]. However, the extent to which AIB1 participates in IGF-I stimulated mRNA translation in breast cancer is not known. The ...
breast cancer cell lines A breast cancer microarray data set (GSE-16975) was analyzed where the breast cancer cell lines were grown to optimal cell densities for RNA extraction and hybridization on Affymetrix microarrays.29 The heat map MMPs, such as for example MMI-166, which is a selective ...
Breast cancer is the most common malignant disease worldwide, with over 2.26 million new cases in 2020. Its diagnosis is determined by a histological review of breast biopsy specimens, which can be labor-intensive, subjective, and error-prone. Artificial Intelligence (AI)—based tools can support...
Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.
Optimal clinical trial design and patient screening: Molecular stratification should be regarded as an essential component of future clinical trial design, unless strong arguments to the contrary can be made. Such stratification should achieve two separate goals. Firstly, to screen out patients at such...
Chronic stress is a known risk factor for breast cancer, yet the underlying mechanisms are unclear. This study explores the potential involvement of microbial and metabolic signals in chronic stress-promoted breast cancer progression, revealing that redu